New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component

In the wake of The New York Times’ April 2 profile portraying MEDVi CEO Matthew Gallagher as a vibe-coded unicorn, the blowback has been swift. Reporting from Futurism, Forrester, Drug Discovery & Development, Business Insider and others has surfaced an FDA warning letter for misbranding compounded GLP-1 drugs, a number of lawsuits and a history… The post New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component appeared first on Drug Discovery and Development.

Continue reading →